NASDAQ:GRCL

Gracell Biotechnologies News Headlines

$12.94
-0.92 (-6.64 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.45
Now: $12.94
$14.94
50-Day Range
$13.00
MA: $19.62
$24.97
52-Week Range
$12.30
Now: $12.94
$33.70
Volume202,536 shs
Average Volume150,995 shs
Market Capitalization$848.39 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Gracell Biotechnologies (NASDAQ GRCL) News Headlines Today

SourceHeadline
Gracell Biotechnologies (NASDAQ:GRCL) Trading Down 3.7%Gracell Biotechnologies (NASDAQ:GRCL) Trading Down 3.7%
americanbankingnews.com - April 14 at 2:34 PM
What Type Of Shareholders Make Up Gracell Biotechnologies Inc.s (NASDAQ:GRCL) Share Registry?What Type Of Shareholders Make Up Gracell Biotechnologies Inc.'s (NASDAQ:GRCL) Share Registry?
finance.yahoo.com - April 8 at 2:00 PM
Gracell Biotechnologies (NASDAQ:GRCL) Stock Price Down 4.9%Gracell Biotechnologies (NASDAQ:GRCL) Stock Price Down 4.9%
americanbankingnews.com - April 6 at 1:26 PM
Gracell Biotechnologies (NASDAQ:GRCL) Reaches New 1-Year Low at $13.10Gracell Biotechnologies (NASDAQ:GRCL) Reaches New 1-Year Low at $13.10
americanbankingnews.com - April 5 at 2:08 PM
Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare ConferenceGracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 5 at 8:57 AM
Gracell Biotechnologies (NASDAQ:GRCL) Sees Unusually-High Trading VolumeGracell Biotechnologies (NASDAQ:GRCL) Sees Unusually-High Trading Volume
americanbankingnews.com - April 1 at 10:54 AM
Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALLGracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
finance.yahoo.com - March 31 at 10:29 AM
Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracells FasTCAR Product Candidates in the U.S.Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.
finance.yahoo.com - March 31 at 10:29 AM
Gracell Biotechnologies (NASDAQ:GRCL) Reaches New 52-Week Low at $14.17Gracell Biotechnologies (NASDAQ:GRCL) Reaches New 52-Week Low at $14.17
americanbankingnews.com - March 30 at 12:42 PM
Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access DayGracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day
benzinga.com - March 17 at 9:15 AM
Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access DayGracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day
finance.yahoo.com - March 17 at 9:15 AM
Gracell Biotechnologies Inc - ADR to Host Earnings CallGracell Biotechnologies Inc - ADR to Host Earnings Call
finance.yahoo.com - March 10 at 9:20 AM
Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate UpdateGracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate Update
finance.yahoo.com - March 9 at 6:34 PM
Gracell Biotechnologies Incorporation (A) Sponsored American Depostary Receipt Repr 5 Shs -A- hosts conference call for investorsGracell Biotechnologies Incorporation (A) Sponsored American Depostary Receipt Repr 5 Shs -A- hosts conference call for investors
markets.businessinsider.com - March 1 at 2:28 PM
Why Gracell Biotechnologies Stock Is Trading Higher TodayWhy Gracell Biotechnologies Stock Is Trading Higher Today
msn.com - February 3 at 5:01 PM
Gracell Biotechnologies Inc. Rings the Opening BellGracell Biotechnologies Inc. Rings the Opening Bell
nasdaq.com - January 19 at 6:07 PM
Gracell Biotechnologies Inc (ADR)Gracell Biotechnologies Inc (ADR)
reuters.com - January 19 at 6:07 PM
Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALLGracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL
finance.yahoo.com - January 19 at 6:07 PM
Gracell Biotechnologies Announces Pricing of Initial Public OfferingGracell Biotechnologies Announces Pricing of Initial Public Offering
finance.yahoo.com - January 15 at 10:46 PM
China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALLChina NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
finance.yahoo.com - January 15 at 10:46 PM
Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy ProductsGracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products
finance.yahoo.com - January 15 at 10:46 PM
Gracell Biotechnologies Inc. (GRCL)Gracell Biotechnologies Inc. (GRCL)
au.finance.yahoo.com - January 11 at 9:39 PM
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.